Taxol transport by human intestinal epithelial Caco-2 cells

Drug Metabolism and Disposition

Volumn 26, Issue 4, 1998, Pages 343-346

  Walle, U Kristina ^b   Walle, Thomas ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ACTIVE TRANSPORT; ARTICLE; CELL MEMBRANE TRANSPORT; CELL STRAIN CACO 2; DIFFUSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG UPTAKE; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; INTESTINE EPITHELIUM; PRIORITY JOURNAL; TRANSPORT KINETICS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL TRANSPORT; CACO-2 CELLS; HUMANS; INTESTINAL ABSORPTION; INTESTINES; PACLITAXEL;

EID: 0031941789     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Artursson P (1990) Epithelial transport of drugs in cell culture. I. A model for studying the passive diffusion of drugs over intestinal absorbtive (Caco-2) cells. J Pharm Sci 79:476-482.
2. Artursson P and Karlsson J (1991) Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175:880-885.
3. Augustijns PF, Bradshaw TP, Gan L-SL, Hendren RW and Thakker DR (1993) Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporin A transport. Biochem Biophys Res Commun 197:360-365.
4. Cavet ME, West M and Simmons NL (1996) Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 118:1389-1396.
5. Cormet E, Barlier AM, Huneau JF, Rubinstein E, Carbon C, Farinotti R and Tomé D (1995) Sparfloxacin secretion across Caco-2 cells involves a multidrug resistance-like mechanism. Drugs 49(Suppl 2):307-309.
6. Cresteil T, Monsarrat B, Alvinerie P, Treluyer JM, Vieira I and Wright M (1994) Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 54:386-392.
7. 1 mice. Cancer Chemother Pharmacol 34:465-471.
8. Fricker G, Drewe J, Huwyler J, Gutmann H and Beglinger C (1996) Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: In vitro-in vivo correlation. Br J Pharmacol 118:1841-1847.
9. Gan L-SL, Moseley MA, Khosla B, Augustijns PF, Bradshaw TP, Hendren RW and Thakker DR (1996) CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: Interaction between the two biochemical barriers to intestinal transport. Drug Metab Dispos 24:344-349.
10. Goldstein JA and de Morais SMF (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285-299.
11. Gupta RS (1985) Cross-resistance of vinblastine-and taxol-resistant mutants of Chinese hamster ovary cells to other anticancer drugs. Cancer Treat Rep 69:515-521.
12. Harris JW, Rahman A, Kim B-R, Guengerich FP and Collins JM (1994) Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54:4026-4035.
13. Horwitz SB, Lothstein L, Manfredi JJ, Mellado W, Parness J, Roy SN, Schiff PB, Sorbara L and Zeheb R (1986) Taxol: Mechanisms of action and resistance. Ann NY Acad Sci 466:733-744.
14. Hosoya KI, Kim KJ and Lee VH (1996) Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers. Pharm Res 13:885-890
15. Hunter J, Hirst BH and Simmons NL (1993a) Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm Res 10:743-749.
16. Hunter J, Jepson MA, Tsuruo T, Simmons NL and Hirst BH (1993b) Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells: Kinetics of vinblastine secretion and interaction with modulators. J Biol Chem 268:14991-14997.
17. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C and Watkins PB (1992) Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 90:1871-1878.
18. Meunier V, Bourrié M, Berger Y and Fabre G (1995) The human intestinal epithelial cell line Caco-2: Pharmacological and pharmacokinetic applications. Cell Biol Toxicol 11:187-194.
19. 2+ channel blockers to enhance inhibition by taxol of growth of drug-sensitive and -resistant Chinese hamster ovary cells. Cancer Treat Rep 70:275-278.
20. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ and Harris JW (1994) Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543-5546.
21. Rowinsky EK and Donehower RC (1995) Paclitaxel (Taxol). N Engl J Med 332:1004-1014.
22. Rowinsky EK, Onetto N, Canetta RM and Arbuck SG (1992) Taxol: The first of the taxanes, an important new class of antitumor agents. Semin Oncol 19:646-662.
23. Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS and Watkins PB (1997) Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1α,25-dihydroxyvitamin D3. Mol Pharmacol 51:741-754.
24. Sonnichsen DS and Relling MV (1994) Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 27:256-269.
25. Walle T (1996) Assays of CYP2C8-and CYP3A4-mediated metabolism of taxol in vivo and in vitro. Methods Enzymol 272:145-151.
26. Walle T, Walle UK, Kumar GN and Bhalla KN (1995) Taxol metabolism and disposition in cancer patients. Drug Metab Dispos 23:506-512.
27. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT and Guzelian PS (1987) Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 80:1029-1036.
28. Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rösch W and Langguth P (1996) Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: Concentration-and dose-dependent absorption in vitro and in vivo. Pharm Res 13:514-522.